Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have previously untreated MDS, AML, or CMML according to the WHO 2016 classification.
MDS patients must have Intermediate (\>3 to 4.5 points), High Risk (\>4.5 - 6) or Very High Risk (\>6 points) disease according to the Revised International Prognostic Scoring System 2012 (IPSS-R).
Clinical indication for treatment with azacitidine for MDS or AML.
You may not be if
Patients with AML who are candidates for standard induction chemotherapy as first line treatment.
Patients with known active CNS leukemia.
Prior treatment with a smoothened inhibitor (SMOi) and/or hypomethylating agent.
